147 related articles for article (PubMed ID: 32843691)
21. FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer.
Wu CC; Beird HC; Zhang J; Futreal PA
PLoS Comput Biol; 2018 Jul; 14(7):e1006266. PubMed ID: 30040819
[TBL] [Abstract][Full Text] [Related]
22. Improved detection of gene fusions by applying statistical methods reveals oncogenic RNA cancer drivers.
Dehghannasiri R; Freeman DE; Jordanski M; Hsieh GL; Damljanovic A; Lehnert E; Salzman J
Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15524-15533. PubMed ID: 31308241
[TBL] [Abstract][Full Text] [Related]
23. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
24. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.
Chen Z; Chen J; Gu Y; Hu C; Li JL; Lin S; Shen H; Cao C; Gao R; Li J; Ha PK; Kaye FJ; Griffin JD; Wu L
Oncogene; 2014 Jul; 33(29):3869-77. PubMed ID: 23975434
[TBL] [Abstract][Full Text] [Related]
25. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
[TBL] [Abstract][Full Text] [Related]
26. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
27. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
28. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
Singh AA; Mandoli A; Prange KH; Laakso M; Martens JH
Oncotarget; 2017 Feb; 8(8):12855-12865. PubMed ID: 28030795
[TBL] [Abstract][Full Text] [Related]
29. KMT2A (MLL) fusions in aggressive sarcomas in young adults.
Yoshida A; Arai Y; Tanzawa Y; Wakai S; Hama N; Kawai A; Shibata T
Histopathology; 2019 Oct; 75(4):508-516. PubMed ID: 31136005
[TBL] [Abstract][Full Text] [Related]
30. Identification of cancer fusion drivers using network fusion centrality.
Wu CC; Kannan K; Lin S; Yen L; Milosavljevic A
Bioinformatics; 2013 May; 29(9):1174-81. PubMed ID: 23505294
[TBL] [Abstract][Full Text] [Related]
31. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.
Reeser JW; Martin D; Miya J; Kautto EA; Lyon E; Zhu E; Wing MR; Smith A; Reeder M; Samorodnitsky E; Parks H; Naik KR; Gozgit J; Nowacki N; Davies KD; Varella-Garcia M; Yu L; Freud AG; Coleman J; Aisner DL; Roychowdhury S
J Mol Diagn; 2017 Sep; 19(5):682-696. PubMed ID: 28802831
[TBL] [Abstract][Full Text] [Related]
32. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
33. Dysregulation of BCL-2 family proteins by leukemia fusion genes.
Brown LM; Hanna DT; Khaw SL; Ekert PG
J Biol Chem; 2017 Sep; 292(35):14325-14333. PubMed ID: 28717011
[TBL] [Abstract][Full Text] [Related]
34. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
35. Kinase domain activation through gene rearrangement in multiple myeloma.
Morgan GJ; He J; Tytarenko R; Patel P; Stephens OW; Zhong S; Deshpande S; Bauer M; Weinhold N; Schinke C; Rasche L; Bailey M; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Zangari M; van Rhee F; Mughal T; Davies FE; Walker BA
Leukemia; 2018 Nov; 32(11):2435-2444. PubMed ID: 29654269
[TBL] [Abstract][Full Text] [Related]
36. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
[TBL] [Abstract][Full Text] [Related]
37. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
38. Diverse
Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.
Kloosterman WP; Coebergh van den Braak RRJ; Pieterse M; van Roosmalen MJ; Sieuwerts AM; Stangl C; Brunekreef R; Lalmahomed ZS; Ooft S; van Galen A; Smid M; Lefebvre A; Zwartkruis F; Martens JWM; Foekens JA; Biermann K; Koudijs MJ; Ijzermans JNM; Voest EE
Cancer Res; 2017 Jul; 77(14):3814-3822. PubMed ID: 28512242
[TBL] [Abstract][Full Text] [Related]
40. The oncogenic fusion landscape in pediatric CNS neoplasms.
Roosen M; Odé Z; Bunt J; Kool M
Acta Neuropathol; 2022 Apr; 143(4):427-451. PubMed ID: 35169893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
